Clarence Patrick Machado

Chief Financial Officer, Medivation.

Companies

ALUMIS INC.Board member Jun 27, 2024 to now¹
ACELYRIN, Inc.Board member May 4, 2023 to now²
Xenon PharmaceuticalsBoard member Nov 5, 2020 to now³
Arcus BiosciencesBoard member Dec 12, 2019 to now⁴
Avalanche BiotechnologiesBoard member Mar 16, 2017 to now⁵
Turnstone Biologics Corp.Board member Jul 20, 2023 to Jul 20, 2023⁶
Chimerix (United States)Board member Jun 23, 2014 to Jun 12, 2023⁷
Turning Point Therapeutics, Inc.Board member May 14, 2019 to Aug 17, 2022⁸
RoivantBoard member Oct 1, 2021 to Oct 1, 2021⁹
Principia Biopharma (United States)Board member Jun 11, 2019 to Sep 28, 2020¹⁰
SCYNEXIS INCBoard member Sep 28, 2015 to Jan 4, 2019¹¹
Sio Gene Therapies Inc.Board member Jul 19, 2017 to Jul 19, 2017¹²
Rocket Pharmaceuticals Inc.Board member Aug 18, 2016 to Jun 21, 2017¹³
MedivationBoard member Jul 1, 2014 to Sep 30, 2016¹⁴
MedivationChief financial officer Jan 30, 2006 to Feb 19, 2014¹⁵
MedivationChief Business Officer Feb 22, 2010 to Feb 22, 2010¹⁶

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

Arcus Biosciences RCUS44,300 shares¹⁷$979.9K at $22.12Jun 11, 2026
Xenon Pharmaceuticals XENE2,645 shares¹⁸$92.0K at $34.78Jun 1, 2026
ALUMIS INC. ALMS10,617 shares¹⁹$65.0K at $6.12Jul 2, 2026
Avalanche Biotechnologies ADVM0 shares²⁰Dec 9, 2025
ACELYRIN, Inc.0 shares²¹May 21, 2025

As of each latest filing. The line shows shares held over time.

Recent filings

Jun 30, 2026Granted 3,553 shares of ALUMIS INC.¹⁹
Jun 11, 2026Granted 5,700 shares of Arcus Biosciences¹⁷
Jun 1, 2026Exercised options 2,645 shares of Xenon Pharmaceuticals¹⁸
Dec 9, 2025U 8,818 shares of Avalanche Biotechnologies²⁰
Jun 10, 2025Granted 13,300 shares of Arcus Biosciences²²
May 21, 2025Granted 7,064 shares of ALUMIS INC.²³
May 21, 2025Returned to company 14,675 shares of ACELYRIN, Inc.²¹
Jun 6, 2024Granted 8,400 shares of Arcus Biosciences²⁴
Oct 4, 2023Other 14,675 shares of ACELYRIN, Inc.²⁵
Jun 15, 2023Granted 6,800 shares of Arcus Biosciences²⁶
Jun 14, 2022Granted 4,100 shares of Arcus Biosciences²⁷

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARALUMIS INC., Board member
2
SEC EDGARACELYRIN, Inc., Board member
3
SEC EDGARXenon Pharmaceuticals, Board member
4
SEC EDGARArcus Biosciences, Board member
5
SEC EDGARAvalanche Biotechnologies, Board member
6
SEC EDGARTurnstone Biologics Corp., Board member
7
SEC EDGARChimerix (United States), Board member
8
SEC EDGARTurning Point Therapeutics, Inc., Board member
9
SEC EDGARRoivant, Board member
10
SEC EDGARPrincipia Biopharma (United States), Board member
11
SEC EDGARSCYNEXIS INC, Board member
12
SEC EDGARSio Gene Therapies Inc., Board member
13
SEC EDGARRocket Pharmaceuticals Inc., Board member
14
SEC EDGARMedivation, Board member
15
SEC EDGARMedivation, Chief financial officer
16
SEC EDGARMedivation, Chief Business Officer
17
SEC EDGARArcus Biosciences shares after the filing of Jun 11, 2026
18
SEC EDGARXenon Pharmaceuticals shares after the filing of Jun 1, 2026
19
SEC EDGARALUMIS INC. shares after the filing of Jul 2, 2026
20
SEC EDGARAvalanche Biotechnologies shares after the filing of Dec 9, 2025
21
SEC EDGARACELYRIN, Inc. shares after the filing of May 21, 2025
22
SEC EDGARForm 4 filed Jun 12, 2025
23
SEC EDGARForm 4 filed May 23, 2025
24
SEC EDGARForm 4 filed Jun 7, 2024
25
SEC EDGARForm 4 filed Oct 6, 2023
26
SEC EDGARForm 4 filed Jun 16, 2023
27
SEC EDGARForm 4 filed Jun 16, 2022